States argue shifting pharmacy benefits from managed care to Medicaid fee-for-service can lead to savings, but removing 340B Drug Pricing Program benefits for managed care drugs can jeopardize essential hospitals’ 340B savings — a critical source of support.

You must be an association member to access this article